15 known cases. View patent page →
Hatch-Waxman ANDA litigation. Consent judgment entered June 15, 2022 (Judge Esther Salas): permanent injunction; all claims/counterclaims dismissed with prejudice. Patents-in-suit expressly included 8,828,427 plus '262, '939, '428, '467, '5939.
Hatch-Waxman ANDA litigation concerning Sandoz ANDA No. 220741. Consent judgment Nov. 17, 2025: permanent injunction barring Sandoz's ANDA product until expiration of patents-in-suit; § 271(e)(1) and Paragraph IV rights expressly preserved.
Hatch-Waxman ANDA litigation concerning Cipla ANDA No. 219718 (1/2/3/4 mg). Consent judgment entered Sept. 11, 2025; case closed Sept. 17, 2025. Patents-in-suit: 8,828,427; 9,993,467; 10,555,939. Injunction until expiration; no damages.
Lead consolidated case for Celgene's pomalidomide ANDA litigation against Hetero; many earlier generic ANDA cases were consolidated into this case.
Celgene's 2018 ANDA infringement case against an unidentified generic pomalidomide filer; consolidated into lead case 17-cv-3387 by Consolidation Order on 2019-01-31.
Celgene's ANDA infringement suit against Apotex; docket shows civil case terminated on 2019-02-08 upon consolidation into lead case 17-cv-3387.
Celgene's 2025 pomalidomide ANDA infringement suit against USV Private Limited; listed as remaining open.
Federal Circuit appeal of the 2:19-cv-05802 venue dismissal; affirmed on Nov. 5, 2021, holding Mylan lacked a regular and established place of business in New Jersey and that the ANDA submission, not the paragraph IV notice letter, is the operative infringing act.
Celgene sued Dr. Reddy's in D.N.J.; the '939 patent was added to the action after issuance, and the case was consolidated with 2:21-cv-02111. Terminated Apr. 6, 2022 per drugpatentwatch.
This Dr. Reddy's action was consolidated into 2:19-cv-15343; it is part of the Pomalyst formulation litigation involving the '939 patent.
One of the March 2020 wave of D.N.J. suits asserting the '939 patent; the defendant is not confirmed in the narrative.
Antitrust action in S.D.N.Y. naming the '939 formulation patent as part of an alleged monopolization scheme. Motion to dismiss granted Mar. 2025; plaintiffs sought leave to amend.
Antitrust action in S.D.N.Y. naming the '939 formulation patent as part of an alleged monopolization scheme. Pending as of the source data.
Antitrust action in S.D.N.Y. naming the '939 formulation patent as part of an alleged monopolization scheme. Pending and consolidated with related Pomalyst antitrust actions.
Antitrust action in S.D.N.Y. naming the '939 formulation patent as part of an alleged monopolization scheme. Pending.